Therapeutic integrin inhibition: allosteric and activation-specific inhibition strategies may surpass the initial ligand-mimetic strategies

Thromb Haemost. 2008 May;99(5):803-4. doi: 10.1160/TH08-03-0194.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Allosteric Regulation
  • Animals
  • Binding Sites
  • Blood Platelets / drug effects*
  • Blood Platelets / metabolism
  • Humans
  • Integrin alphaVbeta3 / antagonists & inhibitors*
  • Integrin alphaVbeta3 / chemistry
  • Integrin alphaVbeta3 / metabolism
  • Ligands
  • Molecular Structure
  • Peptides / metabolism
  • Peptides / pharmacology*
  • Platelet Activation / drug effects
  • Platelet Aggregation Inhibitors / adverse effects
  • Platelet Aggregation Inhibitors / metabolism
  • Platelet Aggregation Inhibitors / pharmacology*
  • Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors*
  • Platelet Glycoprotein GPIIb-IIIa Complex / chemistry
  • Platelet Glycoprotein GPIIb-IIIa Complex / metabolism
  • Protein Binding
  • Protein Conformation

Substances

  • Integrin alphaVbeta3
  • Ligands
  • Peptides
  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex